Gilead Strikes Deal With Mylan to Supply Remdesivir Internationally

Mylan (NASDAQ: MYL) announced on Tuesday that it has entered into a global partnership with Gilead Sciences (NASDAQ: GILD) to manufacture and distribute remdesivir in 127 low- and middle-income countries as a treatment for COVID-19. Remdesivir showed promise against the novel coronavirus in late-stage clinical studies.

Because of the urgent nature of the pandemic, Gilead has indicated its desire to make remdesivir widely available as quickly as possible, and partnering with Mylan will help it accomplish that goal. The pharmaceutical companies have worked together for 15 years in their efforts to fight other infectious diseases including HIV and hepatitis C. Remdesivir is the 10th drug licensed by Gilead to Mylan.

Image source: Getty Images.

Source Fool.com